Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 240

Similar articles for PubMed (Select 8355045)

1.

Comparative pharmacokinetic studies of three asparaginase preparations.

Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ.

J Clin Oncol. 1993 Sep;11(9):1780-6.

PMID:
8355045
2.

Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.

Aldoss I, Douer D, Behrendt CE, Chaudhary P, Mohrbacher A, Vrona J, Pullarkat V.

Eur J Haematol. 2015 Jun 10. doi: 10.1111/ejh.12600. [Epub ahead of print]

PMID:
26095294
3.

Protein-poly(amino acid) precipitation stabilizes a therapeutic protein l-asparaginase against physicochemical stress.

Maruyama T, Izaki S, Kurinomaru T, Handa K, Kimoto T, Shiraki K.

J Biosci Bioeng. 2015 May 12. pii: S1389-1723(15)00160-7. doi: 10.1016/j.jbiosc.2015.04.010. [Epub ahead of print]

PMID:
25979123
4.

Glutaminase activity determines cytotoxicity of l-asparaginases on most leukemia cell lines.

Parmentier JH, Maggi M, Tarasco E, Scotti C, Avramis VI, Mittelman SD.

Leuk Res. 2015 Jul;39(7):757-62. doi: 10.1016/j.leukres.2015.04.008. Epub 2015 Apr 22.

PMID:
25941002
5.

Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines.

Chien WW, Le Beux C, Rachinel N, Julien M, Lacroix CE, Allas S, Sahakian P, Cornut-Thibaut A, Lionnard L, Kucharczak J, Aouacheria A, Abribat T, Salles G.

Sci Rep. 2015 Jan 28;5:8068. doi: 10.1038/srep08068.

6.

Investigation of protective effect of L-carnitine on L-asparaginase-induced acute pancreatic injury in male BALB/c mice.

Kaya I, Citil M, Sozmen M, Karapehlivan M, Cigsar G.

Dig Dis Sci. 2015 May;60(5):1290-6. doi: 10.1007/s10620-014-3461-3. Epub 2014 Dec 14.

PMID:
25502333
7.

Noncovalent PEGylation of L-asparaginase using PEGylated polyelectrolyte.

Kurinomaru T, Shiraki K.

J Pharm Sci. 2015 Feb;104(2):587-92. doi: 10.1002/jps.24217. Epub 2014 Oct 29.

PMID:
25354692
8.

Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.

Angiolillo AL, Schore RJ, Devidas M, Borowitz MJ, Carroll AJ, Gastier-Foster JM, Heerema NA, Keilani T, Lane AR, Loh ML, Reaman GH, Adamson PC, Wood B, Wood C, Zheng HW, Raetz EA, Winick NJ, Carroll WL, Hunger SP.

J Clin Oncol. 2014 Dec 1;32(34):3874-82. doi: 10.1200/JCO.2014.55.5763. Epub 2014 Oct 27.

PMID:
25348002
9.

Preparation and nanoencapsulation of l-asparaginase II in chitosan-tripolyphosphate nanoparticles and in vitro release study.

Bahreini E, Aghaiypour K, Abbasalipourkabir R, Mokarram AR, Goodarzi MT, Saidijam M.

Nanoscale Res Lett. 2014 Jul 9;9(1):340. doi: 10.1186/1556-276X-9-340. eCollection 2014.

10.

Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.

Salzer WL, Asselin BL, Plourde PV, Corn T, Hunger SP.

Ann N Y Acad Sci. 2014 Nov;1329:81-92. doi: 10.1111/nyas.12496. Epub 2014 Aug 5. Review.

11.

How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.

Burke MJ.

Future Oncol. 2014 Dec;10(16):2615-27. doi: 10.2217/fon.14.138.

12.

Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. coli L-asparaginase preparation (MC0609) in Beagle dog.

Borghorst S, Hempel G, Poppenborg S, Franke D, König T, Baumgart J.

Cancer Chemother Pharmacol. 2014 Aug;74(2):367-78. doi: 10.1007/s00280-014-2506-9. Epub 2014 Jun 17.

PMID:
24934864
13.

Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.

Ben Tanfous M, Sharif-Askari B, Ceppi F, Laaribi H, Gagné V, Rousseau J, Labuda M, Silverman LB, Sallan SE, Neuberg D, Kutok JL, Sinnett D, Laverdière C, Krajinovic M.

Clin Cancer Res. 2015 Jan 15;21(2):329-34. doi: 10.1158/1078-0432.CCR-14-0508. Epub 2014 Jun 6.

PMID:
24907114
14.

Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.

Chien WW, Allas S, Rachinel N, Sahakian P, Julien M, Le Beux C, Lacroix CE, Abribat T, Salles G.

Invest New Drugs. 2014 Oct;32(5):795-805. doi: 10.1007/s10637-014-0102-9. Epub 2014 May 15.

PMID:
24829072
15.

Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.

Fernandez CA, Stewart E, Panetta JC, Wilkinson MR, Morrison AR, Finkelman FD, Sandlund JT, Pui CH, Jeha S, Relling MV, Campbell PK.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1307-13. doi: 10.1007/s00280-014-2464-2. Epub 2014 Apr 27.

16.

Anaphylactic reaction to polyethylene glycol-conjugated asparaginase: premedication and desensitization may not be sufficient.

Walenciak J, Mlynarski W, Zalewska-Szewczyk B.

Pediatr Int. 2014 Feb;56(1):130-1. doi: 10.1111/ped.12270. No abstract available.

PMID:
24548205
17.

Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia.

Petersen WC Jr, Clark D, Senn SL, Cash WT, Gillespie SE, McCracken CE, Keller FG, Lew G.

Pediatr Hematol Oncol. 2014 May;31(4):311-7. doi: 10.3109/08880018.2013.876134. Epub 2014 Feb 5.

PMID:
24498943
18.

A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.

Tong WH, Pieters R, Kaspers GJ, te Loo DM, Bierings MB, van den Bos C, Kollen WJ, Hop WC, Lanvers-Kaminsky C, Relling MV, Tissing WJ, van der Sluis IM.

Blood. 2014 Mar 27;123(13):2026-33. doi: 10.1182/blood-2013-10-534347. Epub 2014 Jan 21.

19.

Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.

Plourde PV, Jeha S, Hijiya N, Keller FG, Silverman LB, Rheingold SR, Dreyer ZE, Dahl GV, Mercedes T, Lai C, Corn T.

Pediatr Blood Cancer. 2014 Jul;61(7):1232-8. doi: 10.1002/pbc.24938. Epub 2014 Jan 16.

20.

Chemical modification of L-asparaginase from Cladosporium sp. for improved activity and thermal stability.

Mohan Kumar NS, Kishore V, Manonmani HK.

Prep Biochem Biotechnol. 2014;44(5):433-50. doi: 10.1080/10826068.2013.833110.

PMID:
24397716
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk